

# HYOSCINE BUTYLBROMIDE

Indication	
	<ul style="list-style-type: none"> <li>Spasm of the gastrointestinal, renal and biliary tracts<sup>1</sup></li> </ul>
ORAL	<b>Presentation</b> <ul style="list-style-type: none"> <li>Tablet 10 mg   Tablet 20 mg</li> <li>IV ampoule 20 mg in 1 mL may be given via oral route</li> </ul>
	<b>Dosage</b> <ul style="list-style-type: none"> <li>0.3–0.5 mg/kg every 6–8 hours<sup>2,3</sup></li> </ul>
	<b>Preparation (IV ampoule)</b> <ul style="list-style-type: none"> <li>Draw up 1 mL and make up to 10 mL with water for injection               <ul style="list-style-type: none"> <li>Concentration now equal to 2 mg/mL</li> </ul> </li> <li>Tablet does not disperse easily<sup>4</sup></li> <li>Crush 1 tablet (10 mg) into a fine powder using mortar and pestle or tablet crusher<sup>4</sup></li> </ul>
	<b>Preparation (10 mg tablet)</b> <ul style="list-style-type: none"> <li>Add 10 mL of water for injection and mix well</li> <li>Draw up mixed solution into 10 mL syringe               <ul style="list-style-type: none"> <li>Concentration now equal to 1 mg/mL</li> </ul> </li> <li>Tablet does not disperse easily<sup>4</sup></li> <li>Crush 1 tablet (20 mg) into a fine powder using mortar and pestle or tablet crusher<sup>4</sup></li> </ul>
	<b>Preparation (20 mg tablet)</b> <ul style="list-style-type: none"> <li>Add 10 mL of water for injection and mix well</li> <li>Draw up mixed solution into 10 mL syringe               <ul style="list-style-type: none"> <li>Concentration now equal to 2 mg/mL</li> </ul> </li> </ul>
<b>Administration</b> <ul style="list-style-type: none"> <li>Oral/OGT/NGT</li> <li>Draw up/insert prescribed dose into an oral/enteral syringe</li> <li>Do not administer with other enteral tube medications or feeds (to avoid blockages)</li> <li>Flush enteral tube before and after with 1 mL water for injection</li> </ul>	



Presentation	
	<ul style="list-style-type: none"> <li>Ampoule 20 mg in 1 mL</li> </ul>
INTRAVENOUS	<b>Dosage</b> <ul style="list-style-type: none"> <li>0.3–0.5 mg/kg every 6–8 hours<sup>2</sup></li> </ul>
	<b>Preparation</b> <ul style="list-style-type: none"> <li>Draw up prescribed dose and make up to 1 mL total volume with 0.9% sodium chloride<sup>5</sup></li> </ul>
	<b>Administration</b> <ul style="list-style-type: none"> <li>IV injection over 3 to 5 minutes<sup>5</sup></li> </ul>



<b>Special considerations</b>	<ul style="list-style-type: none"> <li>Contraindications               <ul style="list-style-type: none"> <li>Gastrointestinal mechanical stenoses; paralytic ileus; intestinal atony; megacolon tachycardia<sup>1</sup></li> <li>Porphyria; fructose intolerance; galactose intolerance; Lapp lactase deficiency<sup>6</sup></li> </ul> </li> <li>Caution               <ul style="list-style-type: none"> <li>If urinary outlet obstruction<sup>6</sup></li> </ul> </li> <li>Do not confuse with hyoscine <i>hydro</i>bromide which crosses the blood brain barrier and may cause sedation and delirium<sup>5</sup></li> </ul>
<b>Monitoring</b>	<ul style="list-style-type: none"> <li>Not required</li> </ul>
<b>Compatibility</b>	<ul style="list-style-type: none"> <li>Fluids<sup>5</sup> <ul style="list-style-type: none"> <li>5% glucose, 0.9% sodium chloride</li> </ul> </li> <li>Y-site<sup>5</sup> <ul style="list-style-type: none"> <li>No information</li> </ul> </li> </ul>
<b>Incompatibility</b>	<ul style="list-style-type: none"> <li>Nil known</li> </ul>
<b>Interactions</b>	<ul style="list-style-type: none"> <li>May potentiate anticholinergic effects of other anticholinergic drugs (e.g. atropine, glycopyrrolate or ipratropium)<sup>7</sup></li> <li>Concomitant administration of dopamine antagonists (e.g. domperidone) can reciprocally antagonise the effect of gastrointestinal tract motility<sup>6</sup></li> </ul>
<b>Stability</b>	<ul style="list-style-type: none"> <li>Store below 30 °C. Protect from light<sup>5</sup></li> </ul>

<b>Side effects</b>	<ul style="list-style-type: none"> <li>• Hypersensitivity including anaphylactic shock, facial and periorbital swelling<sup>6</sup></li> <li>• Circulatory: tachycardia<sup>1</sup>, hypotension<sup>6</sup></li> <li>• Digestive: dry mouth<sup>1</sup></li> <li>• Urinary/excretory: impaired micturition or urinary retention<sup>1</sup></li> <li>• Integumentary: dyshidrosis<sup>6</sup></li> <li>• Nervous: eye disorders (e.g. mydriasis, increased intraocular pressure)<sup>6</sup></li> </ul>
<b>Actions</b>	<ul style="list-style-type: none"> <li>• Anticholinergic smooth muscle relaxant with spasmolytic activity<sup>7</sup></li> </ul>
<b>Abbreviations</b>	IV: intravenous, OGT: oral gastric tube, NGT: nasogastric tube
<b>Keywords</b>	Hyoscine butylbromide, buscopan, scopolamine butylbromide

The Queensland Clinical Guideline *Neonatal Medicines* is integral to and should be read in conjunction with this monograph. Refer to the disclaimer. Destroy all printed copies of this monograph after use.

## References

1. British National Formulary for Children (BNFC) online. Hyoscine butylbromide. [Internet]: Royal Pharmaceutical Society; March 2017 [cited 2019 May 01]. Available from: <https://www.medicinescomplete.com>.
2. Shann F. Drug Doses. 17th ed: Collective Pty Ltd; 2017.
3. Children's Health Queensland Hospital and Health Service. A practical guide to palliative care in paediatrics. [Internet]. 2014 [cited 2019 November 07]. Available from: <https://www.childrens.health.qld.gov.au>.
4. Burrige N, Deidun D, editors. Australian Don't Rush to Crush Handbook: Therapeutic Options for People Unable to Swallow Solid Oral Medicines: Society of Hospital Pharmacists of Australia; 2011.
5. Australian Injectable Drugs Handbook. Nicolette Burrige, Keli Symons, editors. Hyoscine butylbromide. 7th ed. [Internet]. New South Wales: Society of Hospital Pharmacists of Australia (SHPA); February 2020 [cited 2020 May 15]. Available from: <https://aidh.hcn.com.au>.
6. MIMS Online. Hyoscine butylbromide. [Internet]: MIMS Australia; September 2018 [cited 2020 May 15]. Available from: <https://www.mimsonline.com.au>.
7. Australian Medicines Handbook. Hyoscine butylbromide. [Internet]. Adelaide: Australian Medicines Handbook Pty Ltd; January 2020 [cited 2020 May 15]. Available from: <https://amhonline.amh.net.au>.

## Document history

ID number	Effective	Review	Summary of updates
NMed20.047-V1-R25	21/08/2020	21/08/2025	Endorsed by Queensland Neonatal Services Advisory Group (QNSAG)

## QR code

